Drug Profile
AC 607
Alternative Names: AC607; Allogeneic multipotent stromal cell treatment - AlloCure; Allogeneic stem cell therapy - AlloCureLatest Information Update: 28 Jul 2015
Price :
$50
*
At a glance
- Originator AlloCure
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Immunomodulators; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute kidney injury
Most Recent Events
- 28 Jul 2015 Discontinued - Phase-II for Acute kidney injury in Canada (Parenteral)
- 28 Jul 2015 Discontinued - Phase-II for Acute kidney injury in USA (Parenteral)
- 01 Aug 2014 Allocure completes a phase II trial in Acute kidney injury in USA and Canada (NCT01602328)